Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma

Journal of Oncology Pharmacy Practice

Volumn 23, Issue 2, 2017, Pages 143-147

  Campbell, Peter ^a   Thomas, Christan M ^a,b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

Author keywords

Hematology; lymphoma; oncology

Indexed keywords

ATAZANAVIR; BELINOSTAT; CLOZAPINE; CREATININE; DIPYRONE; WARFARIN; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; SULFONAMIDE;

ANEMIA; CANCER CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEVER; HUMAN; MULTICENTER STUDY (TOPIC); MULTIPLE ORGAN FAILURE; NAUSEA; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; BLOOD; BLOOD CELL COUNT; LYMPHOMA, T-CELL, PERIPHERAL; PRACTICE GUIDELINE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, T-CELL, PERIPHERAL; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES AS TOPIC; SULFONAMIDES; TREATMENT OUTCOME;

EID: 85011850847     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155216634178     Document Type: Review

References (30)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, Lyon, France: International Agency for Research on Cancer, 2008.
2. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors. J Clin Oncol 2013; 31: 1970-1976.
3. Coffier B, Federico M, Caballero D, et al. Therapeutic options for relapsed or refractory peripheral T-cell lymphoma. Cancer Treat Rev 2014; 40: 1080-1088.
4. Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20: 1533-1538.
5. Rodríguez J, Conde E, Gutiérrez A, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: A prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007; 79: 32-38.
6. Thompson CA,. Belinostat approved for use in treating rare lymphoma. Am J Health Syst Pharm 2014; 71: 1328-1328.
7. Poole RM,. Belinostat: First global approval. Drugs 2014; 74: 1543-1554.
8. Beleodaq (Belinostat) package insert. Irvine, CA: Spectrum Pharmaceuticals, 2014.
9. Ropero S, Esteller M,. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1: 19-25.
10. SOLVO-TopoTarget-01. In vitro interaction studies of one test article with P-gp (MDR1/ABCB1) in the vesicular transport assay and in Bidirectional Transport (Papp) Studies on Caco-2 monolayers. Internal report 2010.
11. Foss F, Advani R, Duvic M, et al. A phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol 2015; 168: 811-819.
12. Reimer P, Chawla S,. Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma. J Hematol Oncol 2013; 6: 69-69.
13. Brentuximab vedotin (Adcetris) package insert. Bothell, WA: Seattle Genetics, 2015.
14. Pralatrexate (Folotyn) package insert. Westminster, CO: Allos Therapeutics, 2011.
15. Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2012; 62: 4916-4921.
16. Gryder BE, Sodji QH, Oyelere AK,. Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012; 4: 505-524.
17. Lane AA, Chabner BA,. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459-5468.
18. Miller TA, Witter DJ, Belvedere S,. Histone deacetylase inhibitors. J Med Chem 2003; 46: 5097-5116.
19. National Comprehensive Cancer Network. Non-Hodgkin lymphoma (Version 2.2015). http://www.nccn.org/professionals/physician-gls/pdf/nhl.pdf (accessed 12 April 2015).
20. ClinicalTrials.gov. Belinostat. http://clinicaltrials.gov/ct2/results?term=belinostat&Search=Search (accessed 13 April 2015).
21. Chun P. Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch Pharm Res 2015. Epub ahead of print.
22. Tula-Sanchez AA, Havas AP, Alonge PJ, et al. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors. Cancer Biol Ther 2013; 14: 949-961.
23. Kaufman JL, Fabre C, Lonial S, et al. Histone deactylase inhibitors in multiple myeloma: Rationale and evidence for their use in combination therapy. Clin Lymphoma Myeloma Leuk 2013; 13: 370-376.
24. Kirschbaum MH, Foon KA, Frankel P, et al. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: A California Cancer Consortium Study. Leuk Lymphoma 2014; 55: 2301-2304.
25. Savickiene J, Treigyte G, Valiuliene G, et al. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells. Anticancer Drugs 2014; 25: 938-949.
26. Lin SF, Lin JD, Chou TC, et al. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. PLoS One 2013; 8: e77684-e77684.
27. Hainsworth JD, Daugaard G, Lesimple T, et al. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. Cancer 2015. Epub ahead of print.
28. Kim MJ, Lee JS, Park SE, et al. Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: A role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase. J Urol 2014. Epub ahead of print.
29. Thomas A, Rajan A, Szabo E, et al. A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: A clinical and translational study. Clin Cancer Res 2014; 20: 5392-5402.
30. Dizon DS, Blessing JA, Penson RT, et al. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2012; 125: 367-371.